The Lankenau Institute for Medical Research
The Lankenau Institute for Medical Research (LIMR) is pleased to announce the most recent addition to its biotech incubator, CD Diagnostics Inc., a company co-founded by LIMR faculty member and Lankenau Medical Center orthopedic surgeon Carl Deirmengian, M.D. Dr. Deirmengian has developed a prognostic test for joint fluid so patients having joint replacement surgery can be treated with antibiotics to stem an infection before it arises. CD Diagnostics has patented this technology, which enables clear, accurate, and rapid diagnosis of infected joints.
Pain in the joints is frequently misdiagnosed and is a significant contributor to rising health care costs. The most common causes of joint pain are infection, injury, gout, and rheumatoid arthritis. Joint infection (septic arthritis) is a particularly difficult problem to properly identify with current technology, yet it can be catastrophic to joint health if not found and treated.
Currently, few tests are available to conclusively determine the cause of joint pain. In many cases, a blood test is performed, which frequently yields vague and ambiguous results. CD Diagnostics’ product CygnaSure tests the joint fluid at the site of the pain response, giving accurate and more definitive results quickly. As explained by Dr. George C. Prendergast, the President and CEO of LIMR, “Dr. Deirmengian’s new test offers a simple and elegant tool to help physicians diagnose and treat the source of joint pain in their patients. LIMR is delighted to have the opportunity to help CD Diagnostics achieve its goals to develop and receive FDA approval of this test for patients.”
About Lankenau Institute for Medical Research
Founded in 1927, the Lankenau Institute for Medical Research (LIMR) is an independent, non-profit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Medical Center. Part of Main Line Health, LIMR is one of the few freestanding, hospital-associated medical research centers in the nation. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease and diabetes. They use this information to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. LIMR is also committed to extending the boundaries of human health and well-being through technology development and the training of the next generation of scientists and physicians. For more information, please visit www.limr.org.